Modification of the Human Colon and Oral Microbiome by Allogenic HSCT
NCT ID: NCT03942159
Last Updated: 2020-04-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
15 participants
OBSERVATIONAL
2019-05-14
2023-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
FMT In High-Risk Acute GVHD After ALLO HCT
NCT04139577
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
NCT04629430
Alterations in Intestinal Microbiota, Metabolites, and Immune Cells in Allo-HSCT
NCT06143501
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
NCT04935684
Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT
NCT02398708
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Donors
HLA-matched or haploidentical nursing relative donors
No interventions assigned to this group
Patients
recipients of allogeneic HSCT
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* nursing healthy donors 3-55 y.o.
Exclusion Criteria
* graft rejection
* previous HSCT
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Maschan, PhD
Role: PRINCIPAL_INVESTIGATOR
National Research Center for Pediatric Hematology , Moscow, Russian Federation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
Moscow, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCHPOI-2019-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.